CCM
ATRA icon

Camber Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Camber Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-56,000
Closed -$18.1M – 33
2020
Q3 		$18.1M Hold
56,000
– – 0.96% 27
2020
Q2 		$20.4M Sell
56,000
-3,150
-5% -$796K 1.17% 23
2020
Q1 		$12.6M Sell
59,150
-58,850
-50% -$18.7M 0.75% 25
2019
Q4 		$48.6M Hold
118,000
– – 2.47% 20
2019
Q3 		$41.7M Buy
118,000
+38,000
+48% +$14.2M 2.19% 20
2019
Q2 		$40.2M Hold
80,000
– – 1.87% 22
2019
Q1 		$79.5M Buy
80,000
+4,000
+5% +$3.72M 3.96% 10
2018
Q4 		$66M Buy
76,000
+11,200
+17% +$10.4M 3.13% 12
2018
Q3 		$67M Hold
64,800
– – 2.87% 13
2018
Q2 		$59.5M Buy
64,800
+132
+0.2% +$142K 2.29% 20
2018
Q1 		$63.1M Buy
64,668
+43,248
+202% +$39.4M 3.1% 13
2017
Q4 		$9.69M Hold
21,420
– – 0.47% 29
2017
Q3 		$8.86M Hold
21,420
– – 0.56% 22
2017
Q2 		$7.5M Buy
21,420
+16,420
+328% +$6.33M 0.37% 31
2017
Q1 		$2.57M Buy
+5,000
New +$2.07M 0.1% 30

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Camber Capital Management's ATRA Position: Q4 2020 in Review

Camber Capital Management sold out of Atara Biotherapeutics (ATRA) in Q4 2020, closing a stake of 56,000 shares — an estimated $18.1M sold.

Camber Capital Management first reported a position in ATRA in Q1 2017 and held it in 15 quarters. The position peaked at $79.5M in Q1 2019. 148 funds tracked by Wall St. Rank hold ATRA as of Q4 2020.

  • Camber Capital Management reported no remaining Atara Biotherapeutics position as of Q4 2020 after selling out during the quarter.
  • Camber Capital Management sold 56,000 Atara Biotherapeutics shares in Q4 2020, an estimated $18.1M.
  • Camber Capital Management first reported a position in Atara Biotherapeutics in Q1 2017 and held it in 15 quarters.
  • Camber Capital Management's Atara Biotherapeutics position peaked at $79.5M in Q1 2019.
  • 148 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2020.

Based on Camber Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.